/ /

  • linkedin
  • Increase Font
  • Sharebar

    European study with microstent demonstrates lowered IOP, use of fewer drugs

    Data focuses on patients with combined cataract surgery, device implantation


    In cohort 2, the mean IOP stayed the same postoperatively. However, by month 36, the mean number of medications used had dropped to one.

    “Of note, we see that the percentage of patients on 0 to 1 medications at baseline was only 31.6% and then increased to 64.1% by 36 months,” Dr. Sarkisian said. “Moreover, at 36 months the number of patients on zero medications was 45%.”

    The most commonly seen adverse event was device obstruction (9.4%).

    “There were 2 reports of transient device obstruction by blood within the first postoperative week,” Dr. Sarkisian said. “However, in the vast majority of cases (n = 19), obstruction appeared to have been related to intraoperative device positioning that was more posterior than optimal and, over time, iris tissue overgrew some portion of the device lumen, which was resolved by use of a YAG laser.

    “Also, retinal complications occurred in 4.1% of patients, but only one case was related to the CyPass, and was due to hypotony that resolved after device explantation,” he said.

    Although visual loss occurred in some patients, none of it was related to the implant.

    “The three-year safety profile gives long-term evidence of compatibility with cataract surgery and the potential to employ this therapy earlier in the glaucoma treatment paradigm,” Dr. Sarkisian said.


    Steven R. Sarkisian Jr., MD

    E: [email protected]

    This article was adapted from Dr. Sarkisian’s presentation at the 2016 meeting of the American Academy of Ophthalmology. Dr. Sarkisian is a consultant for Alcon Laboratories.



    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results